B
loodstream infection (BSI) is a serious and preventable health outcome that accounts for over 1% of all hospitalizations in the United States and is associated with a fatality rate variously estimated at 20-50%. 1, 2 The frequency of BSI has been increasing over the past several decades, 2 and prevention of nosocomial BSI due to contamination introduced within the hospital setting is a primary concern for health care officials. [3] [4] [5] Intravenous administration of drugs and parenteral nutrition has been associated with an approximately 10-fold increase in the risk of nosocomial BSI among hospitalized patients. 1 Manual admixture of drugs and diluents in preparation for i.v. infusion has been identified as a potential source of contamination. 6 Manufactured closed drug-delivery modalities decrease the need for manual admixture and reduce the risk of contamination, thereby decreasing the risk of BSI associated with i.v. drug exposure. [7] [8] [9] In closed systems, also known as premixed or ready-to-use (RTU) systems, the drug and diluents are already mixed and packaged (possibly frozen and thawed to extend shelf life) in a bag ready for i.v. delivery.
Am J Health-Syst Pharm-Vol 70 Jun 1, 2013 Delivery systems activated at the point of care (POC) allow drug admixture to occur at the time of administration; this is achieved by connecting a single-dose drug vial to a specially designed bag and then breaking the seal in the tube between the vial adaptor and the bag to allow the transfer of diluent into the vial, reconstituting the drug. The effect of POC-activated i.v. drug delivery on the risk of hospital-acquired BSI has not been well studied in the general population.
The objective of the study described below was to assess the impact of both POC-activated and closed i.v. drug delivery on the risk of hospital-acquired BSI in the general population. Because closed systems require the least manual manipulation, with the only human contact occurring when the health care provider connects the i.v. line, we expected that this i.v. delivery route would be associated with the lowest risk of hospital-acquired BSI. As POC-activated systems require the extra step of connecting the drug vial to the admixture bag, their use was expected to pose a slightly higher infection risk relative to the use of closed systems but less risk than that posed by traditional manual admixture (also known as "open") systems. We evaluated these hypotheses by conducting a retrospective cohort study using the Premier Perspective Comparative Database of U.S. inpatients (Premier Inc., Charlotte, NC).
Methods
Data source. The study was conducted using 2007-09 data from the Premier Perspective database, which includes claims data from more than 600 hospitals, with more than 5 million hospital discharges added annually. For these discharges, there are more than 5 Any patient for whom there was documented evidence of BSI or another infection at the time of admission was excluded from the study. BSI or another infection at the time of hospital admission was assumed if the record contained either an admitting ICD-9 diagnosis code (Appendix B) for infection or evidence of infection within 48 hours of admission (as determined by a combination of blood culture and i.v. antibiotic billing charges). If the date of BSI diagnosis could not be confirmed using data in the billing charges, the patient was excluded from the analysis. Thus, the study population included only patients for whom there was no evidence of infection at admission or within 48 hours after admission. Due to the limited use of POCactivated and closed systems-the median proportion of use was zero for both-any exposure to these systems prompted the automatic assignment of patients to the applicable high-exposure categories. Thus, the final comparison groups for the study consisted of (1) patients with exposure to only open i.v. administration systems, who were referred to as the "Open Only" group, (2) patients with exposure to only POC-activated systems, dubbed the "POC-Activated (No Closed)" group, (3) patients with exposure to only closed systems, referred to as the "Closed (No POC)" group, and (4) patients with exposure to both POCactivated and closed systems, termed the "POC-Activated and Closed" group. The classification of patients with some exposure to open systems into the POC-Activated (No Closed) and Closed (No POC) groups was permitted, as long as at least one of their i.v. drug administrations was delivered via a POC-activated or closed system. Several of the drugs offering both POC-activated and closed-system administration options were antiinfective medications. Because the use of i.v. antiinfectives could have reflected either the treatment of hospital-acquired BSI (the outcome of interest) or a non-BSI-related exposure unrelated to BSI (i.e., the treatment of an infection other than a BSI), these drugs were considered separately from other i.v. drugs. We also conducted a sensitivity analysis including only patients who did not receive i.v. antibiotics before BSI diagnosis (or, in the case of patients without BSI, did not receive any antibiotics).
Risk factors.
We examined several factors shown to influence the risk of hospital-acquired BSI, including hospital length of stay (LOS), days in the intensive care unit (ICU), surgical patient status, central venous catheter (CVC) use, mechanical ventilator use, trauma patient status, hemodialysis, malnutrition, and other infections. 1 Hospital LOS and ICU days were calculated from billing claims for room and board charges, and surgery was inferred for patients with at least one billing charge from the surgery department. ICD-9 and CPT codes for other risk factors are provided in Appendix B.
For patients with hospitalacquired BSI, we calculated risk factors using only prediagnosis information. For instance, only the LOS and days in the ICU before the diagnosis date were counted for patients with hospital-acquired BSI. Similarly, only data on surgery, CVC use, ventilator use, and hemodialysis prior to a diagnosis of hospital-acquired BSI were included in the risk factor analysis.
In addition to categorizing patients into analysis groups based on their relative exposures to various i.v. drug administrations, we created variables summarizing the absolute amount of i.v. exposure to be considered as risk factors. These included the total count of i.v. drugs administered per patient, both as a continuous variable and categorized into quartiles based on the distribution of the data. Values are provided for total exposure to the study drugs, as well as for antibiotic and nonantibiotic study drugs separately. We also quantified exposures to additional i.v. products, including items such as i.v. drugs not under study and parenteral nutrition and supplements. Additional i.v. exposures were identified from claims with a billing charge code containing the word "parenteral" in the product description.
Outcome ascertainment. Hospitalacquired BSI was defined using ICD-9 diagnosis codes (Appendix B) in combination with billing charges for blood cultures and i.v. antibiotics. To limit the analysis to hospitalacquired BSI, patients whose case data contained evidence of infection within 48 hours of admission were excluded from the study, and we only included data on events occurring after the second inpatient service day. 10 Because ICD-9 diagnosis codes in the Premier database are not linked to the day of diagnosis, an algorithm was devised to estimate the date of the BSI event. Specifically, if the patient had an ICD-9 diagnosis code for BSI and a billing charge for a blood culture, then the service date of the blood culture charge was considered the diagnosis date. If a patient with BSI had multiple blood culture charges, then the service date of the first culture charge followed by an i.v. antibiotic charge within two days was considered the diagnosis date. If the patient had a BSI diagnosis but no blood culture charge was recorded, the first service date associated with a billing charge for i.v. antibiotic therapy was considered the diagnosis date.
Any patient whose BSI diagnosis date was on or before the second day of the hospital stay was considered to have been admitted with BSI and thus excluded from the analysis. Similarly, patients with an ICD-9 diagnosis code for BSI but no subsequent blood culture or i.v. antibiotic charges were excluded because the diagnosis date was undefined (per the above definition) and we were thus unable to determine whether the infection was present on admission.
Analytical methods. Baseline demographic, comorbidity, and hospitalization characteristics were analyzed by i.v. drug exposure category using means with standard deviations and medians with ranges for continuous variables; raw counts with percentages were used for the analysis of categorical measures. For all comparative analyses, patients (<10% of the population) , the OR provides a good estimate of relative risk, 11 and that was the case in this study. Multivariate analyses were repeated for patients who did not receive i.v. antibiotics prior to or without a BSI event. All analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, NC), with the a priori level of significance set at 0.05.
Results
Using the 2007-09 Premier database, we identified just over 10 million hospitalized patients who received at least one i.v. drug. Nearly half these patients were excluded from our analysis on the basis of data indicating an admission to a hospital or other provider facility where the use of POC-activated or closedsystem i.v. drug delivery products could not be identified (because these products were not used in the facility or charge-description details were insufficient to allow the classification of the i.v. drug exposure). After excluding patients with evidence of infection at or within 48 hours after admission (9.4%), the final cohort included 4,073,864 patients.
Among patients included in the study, 262,209 (6.4%) received i. (Table 1) .
With regard to baseline demographic information, patients who received i.v. drugs only via open systems were younger, more likely to be female, less likely to be from the Midwestern region of the United States, and more likely to be on Medicaid than patients who received i.v. drugs via a combination of delivery systems (Table 2) . Patients who received any POC-activated or closed-system drug products were more likely to have elective admissions (Table 2) .
Patients with exposure to POCactivated and closed administration systems had a longer LOS, were more likely to be in the ICU, and had higher rates of all BSI risk factors, including surgery, trauma, CVC use, mechanical ventilation, hemodialysis, malnutrition, and other infections ( Table 2) .
We determined that BSI occurred in 20,251 (0.5%) of patients who received at least one i.v. exposure to a drug under study. Patients in the POC-Activated and Closed group, as well as those in the Closed (No POC) group, had a significantly reduced risk of BSI (risk reductions of 0.2% and 0.3%, respectively) compared with the Open Only group (0.5%); those risk reductions corresponded to unadjusted RR values of 0.39 (95% CI, 0.21-0.72) and 0.63 (95% CI, 0.59-0.67), respectively ( Table  3 ). The unadjusted risk of BSI was similar in the POC-Activated (No Closed) and the Open Only groups. RRs for BSI were fairly consistent among patients receiving drugs in each of the examined classes.
After adjustment for selected confounding variables, both i.v. drug exposure via POC-activated systems and i.v. exposure via closed systems were associated with a significantly reduced risk of BSI compared with i.v. drug exposure exclusively via open systems (Table 3) . Patients who received drugs via both POCactivated and closed systems had the lowest rate of hospital-acquired BSI, with an 88% reduction in odds (OR, 0.12; 95% CI, 0.06-0.23, p < 0.0001). Considered separately, the use of POC-activated systems alone and closed systems alone reduced the risk of hospital-acquired BSI by 16% and 12%, respectively. A total of 2,153,321 patients (52.9% of the original cohort) had no exposure to i.v. antibiotics prior to BSI diagnosis or discharge and were included in the sensitivity analysis. Among these patients, having i.v. drug exposure from closed systems was associated with an 86% reduction in the risk of hospital-acquired BSI, and exposure to POC-activated systems was associated with a 49% risk reduction. None of the patients included in the sensitivity analysis had exposure to both types of systems during the hospitalization.
Discussion
Nosocomial BSI is a serious and often preventable adverse event for hospitalized patients. 12, 13 Simple solutions, including systematic hand washing and training programs in drug administration, are important first steps in reducing the risk of BSI. 1, 13 New technologies that reduce the amount of manual manipulation required to administer i.v. solutions can provide additive reductions in BSI risk. In the large population of U.S. hospitalized patients receiving i.v. drugs that was evaluated in our study, the use of POC-activated and closed drug delivery systems was infrequent, with 90% of patients having exposure to only open systems. Even among patients with at least one exposure to a POC-activated or closed system, the proportion of all i.v. drugs administered via open systems averaged two thirds. The results of this study demonstrated that, conditional on total i.v. exposures, the increased use of closed and POCactivated i.v. drug delivery systems was associated with a significant reduction in the risk of hospitalacquired BSI.
These results are supportive of a growing body of literature. For patients with indwelling catheters for long-term medication delivery, closed-hub catheter systems have been shown to substantially reduce the risk of BSI. 7, 8, 14 More recently, closed infusion containers have been shown to reduce the risk of central line-associated BSI compared with open systems. [15] [16] [17] Similarly, patients receiving premixed parenteral nutrition solutions have been shown to have a substantially reduced risk of BSI relative to those receiving traditionally compounded parenteral nutrition. 18 Whether or not other delivery systems that limit manual admixture of drug and solution have a beneficial impact on BSI rates has not been extensively examined. A study of 300 infants did not find a BSI risk-reduction benefit with the use of a closed system of drug administration, 9 but these results may not be generalizable to adult populations. The study described here evaluated a diverse cross-section of U.S. hospitalized patients of all ages. Hospitals may wish to consider expanding the use of POC-activated and closed drug delivery systems in light of potential cost savings as well as patient safety benefits.
In our study, even though they were older and sicker at baseline by nearly all health-related measures (e.g., hospital LOS, ICU days, all additional BSI risk factors), patients receiving drugs via both POCactivated and closed systems, as well as those receiving closed-system administrations only, had lower rates of BSI than those receiving opensystem administrations-even before adjusting for health status. Patients with exposure to both POC-activated and closed drug delivery systems derived the greatest risk-reduction benefit relative to patients with only open-system exposure (in this group, a larger proportion of administrations were given via closed versus Estimates from logistic regression models include all covariates that modified the association between bloodstream infection and total i.v. exposure group by ≥10%. RR = risk ratio, CI = confidence interval, OR = odds ratio. It is curious that the combined use of both POC-activated and closed delivery systems was associated with a greater risk reduction than the use of closed systems exclusively. Given that closed systems, by design, require less manual handling (and thus have fewer potential contamination sites), we expected that their exclusive use would confer significant risk reductions relative to both POCactivated and open systems. However, our findings did not support that hypothesis. One possible explanation for this unexpected finding is that patients receiving i.v. administrations from both closed and POC-activated systems constituted a very small percentage of the study population (0.12%); this may have precluded full adjustment and skewed the results.
Risk of Bloodstream Infection in Patients Given
Another limitation of the study pertains to the data regarding antibiotic administrations, which can be both a source of and a treatment for hospital-acquired BSI. After excluding patients who received i.v. antibiotics before their BSI diagnosis, i.v. drug exposure via closed systems was associated with an 86% reduction in BSI risk, and i.v. drug exposure via POC-activated systems was associated with a 49% risk reduction. Among patients not receiving i.v. antibiotics, there were insufficient patients receiving both types of exposure to compute an effect estimate; this may indicate misclassification pertaining to difficulties in identifying BSI cases using claims data. There is a financial incentive to record services accurately, but the documentation of a BSI diagnosis code could indicate a case of suspected BSI. It is also possible that billed antibiotics were administered prophylactically, particularly for surgical 19 and oncology patients. 20 Moreover, a documented blood culture could have been contaminated, thereby obscuring the source of BSI. For any of these reasons, a patient could have been included in our study as a BSI case in the absence of a confirmed diagnosis.
Another study limitation was that we did not control for all potential risk factors. In particular, information about infection-control practices that may have been in effect at institutions included in the analysis was unavailable in the claims database. In addition, other factors potentially associated with BSI risk (e.g., stem cell transplantation, neutropenia, chemotherapy use, number of i.v. lines, duration of line placement) were not controlled for. Although we do not readily conceive of these limitations having a major impact on the results, the effect of uncontrolled factors is uncertain.
Conclusion
Use of POC-activated and closed systems for i.v. drug delivery was associated with a significantly reduced risk of hospital-acquired BSI compared with exclusive use of open systems in a large population of hospitalized patients.
